The unprecedented increase in preclinical studies necessitates high-throughput, inexpensive, and straightforward methods for evaluating diseased tissues. Near-infrared imaging of live subjects is a versatile, cost-effective technology that can be effectively used in a variety of pathologic conditions. We have characterized an inexpensive optoelectronic chemical, IR-820, as an infrared blood pool contrast agent to detect and quantify diseased tissue in live animals. IR-820 has maximal excitation and emission wavelengths of 710 and 820 nm, respectively. IR-820 emission is significantly improved in vivo on serum binding to albumin, and elimination occurs predominantly via the gastrointestinal tract. We demonstrate the utility of this contrast agent for serially imaging of traumatized tissue (muscle), tissue following reperfusion (eg, stroke), and tumors. IR-820 can also be employed to map regional lymph nodes. This novel contrast agent is anticipated to be a useful and an inexpensive tool for screening a wide variety of preclinical models of human diseases.
S ERIAL LIVE IMAGING is emerging as an important part of preclinical studies. Among imaging modalities, optical imaging is becoming one of the most versatile and informative methodologies, especially when coupled with contrast agents. Near-infrared (NIR) contrast agents are ideally suited to live animal studies owing to the deep tissue penetration and reduced light scattering. 1 Classically, NIR blood pool contrast agents have been used in retinal angiography 2 and for clinical determination of cardiac output 3 and hepatic function. 4 Clinical NIR contrast agents, such as indocyanine green, have also been used in preclinical development. Other similarly effective but more costly blood pool contrast agents have been developed specifically for preclinical use. 5, 6 NIR optical imaging takes advantage of the ''window of transparency'' between 700 and 900 nm, where light absorption is at a minimum in tissue, along with comparatively lower scattering. These characteristics allow NIR light to travel . 1.5 cm in tissue before being completely absorbed. 7 Herein we describe a novel, inexpensive blood pool contrast agent and its use in differentiating between normal and diseased tissue in live animals using NIR fluorescence imaging.
Methods

Contrast Agent
The commercially available optoelectronic chemical IR-820 (C 46 H 50 ClN 2 NaO 6 S 2 ) was purchased from Sigma-Aldrich (catalog# 543365, St. Louis, MO). IR-820 has a molecular weight of 849.47 atomic mass units (amu) and is normally used as a laser and NIR dye. For each experiment, the powdered IR-820 was freshly mixed with phosphate-buffered saline (PBS) to a final concentration of 0.2 mM, and 100 mL of this solution was used for injecting into experimental animals.
Optical Imaging Protocol
The Xenogen IVIS Spectrum system (Caliper, Xenogen, Alameda, CA) was used to capture images for all experiments. The instrument employs a scientific grade, cryogenically cooled charge-coupled device camera, which has a low-noise, 16 -bit digitized electronic readout. All images were acquired using the epi-illumination method at excitation wavelength of 710 nm and emission wavelength of 820 nm unless otherwise stated. The camera settings were kept constant at 1-second exposure time, 2 3 2 binning, 12.6 cm field of view, and f/stop of 1/2. The data were acquired and analyzed using the manufacturer's Living Image 3.2 software.
Excitation and Emission Spectra
To determine the excitation and emission spectra for IR-820, the solution was loaded into a clean cuvette and was imaged after 15 minutes. The images were acquired using a set of excitations ranging from 435 to 745 nm (windows of 35 nm) and emission filters ranging from 500 to 840 nm (windows of 20 nm).
Protein Interaction with IR-820
To determine the relative size of serum proteins that bind IR-820, serum-IR-820 samples were separated on a 10% sodium dodecyl sulfate (SDS) polyacrylamide gel, stained with Coomassie blue, and imaged.
In Vivo Pharmacokinetics of IR-820
All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals 8 and were approved by the Institutional Animal Care and Use Committee (IACUC) at The University of Texas Health Science Center at San Antonio (UTHSCSA) and the South Texas Veterans Health Care System. For pharmacokinetics analysis, two groups of four Hairless SKH1/SKH1 mice were used. The first group was injected with IR-820 by intravenous tail vein injection, whereas the second was injected intraperitoneally. Both groups were serially imaged for 8 days. Throughout this study, unless otherwise stated, animals were imaged using the same anesthesia protocol, 2% isoflurane in 100% oxygen at 2.5 L/min. Body temperature was maintained at 37uC by a heated stage.
Response to Increased Vascular Permeability
For vascular permeability experiments, the skin overlying the dorsal ribcage of a female C57BL/6 mouse (Taconic, Hudson, NY) was shaved 3 days prior to the imaging experiment. Vascular permeability was increased by intradermal injection of 50 mL of histamine (10 and 500 mM) diluted in PBS using a 30-gauge needle onto the dorsal surface of the mouse with histamine or PBS. After 10 minutes, IR-820 was administered by intravenous injection as described above. An area on the dorsal side that did not receive any injection was used to determine the baseline fluorescence. Imaging was performed in triplicate on a single mouse 30 minutes after histamine injection.
Muscle Injury Model Using Cardiotoxin
Hairless SKH1/SKH1 mice were bred at the UTHSCSA; the original breeders for this colony were obtained from Charles River Laboratories (Wilmington, MA). Twelveweek-old female mice received intramuscular injections to the anterior compartment muscles below the knee of the right hindlimb with either 100 mL cardiotoxin (CTX) (2.5 mM; Calbiochem, San Diego, CA) to induce myonecrosis or normal saline (NS) injections to control for the needle trauma caused by the injection; the left hindlimbs in these animals served as noninjected controls.
To determine the kinetics of IR-820 imaging in injured muscle, three groups of mice underwent baseline imaging. Each mouse received an intraperitoneal injection of IR-820 and was imaged 30 minutes later. Immediately after the imaging, the mice received right anterior compartment injections of CTX, NS, or no injections (noninjured), three to four mice/group. The mice were serially imaged at 1, 2, and 6 hours post-CTX or -NS injection with daily imaging thereafter for 8 days.
To assess for ongoing vascular leak, an additional group of mice received two CTX injections into the anterior compartment of the right hindlimb and similar volumes of NS into the anterior compartment of the left hindlimb after baseline imaging (two mice). Twenty-four hours after CTX and NS injection, the mice were imaged and received an intraperitoneal injection of IR-820. The mice were serially imaged at 1, 2, and 6 hours after IR-820 injection, with daily imaging for 6 days.
A separate group of mice received CTX injection and were euthanized 1 hour, 3 days, and 7 days after CTX injection for histology studies (n 5 1-2 mice/time point). Bilateral anterior compartment muscles were removed en bloc, fixed in 10% neutral buffered formalin, paraffin embedded, and processed by routine histologic procedures.
Statistical Analysis
To determine whether the fluorescence intensities are dose dependent, the Student t-test was performed using Excel on the total flux values obtained from all four sites in vascular permeability experiment ( Figure 1E ).
SAS software (SAS Institute, Cary, NC) was used for all statistical analyses related to muscle injury experiment. The results from corresponding time points of each group were averaged and used to calculate descriptive statistics (mean 6 standard deviation). All statistical testing was two-sided, with a significance level of 5%.
The absolute value or paired differences of the serially measured signal intensities were compared between Figure 1 . IR-820 is a commercially available optoelectronic chemical with promising applications in biologic (preclinical) optical imaging. A, Spectra for free IR-820 reveal excitation and emission peaks at 710 and 820 nm, respectively. Inset shows the molecular structure of IR-820. B, IR-820 and protein interaction visualized using 10% SDS PAGE stained with Coomassie blue shows fluorescence signal in all serum samples at a size similar to bovine serum albumin (BSA). The scale bar ranges from 1 3 10 6 to 1 3 10 7 photons/s/cm 2 / steradian. C, Whole-body pharmacokinetics of IR-820 in hairless mice. Mice injected with 100 mL of IR-820 contrast agent intravenously through tail vein (top set) and intraperitoneal injection (bottom set). For both sets, the first image is prior to injection of IR-820, and time thereafter is in reference to IR-820 injection. The images are displayed with a minimummaximum scale of 4 3 10 8 to 4 3 10 9 photons/s/cm 2 /steradian. D, The animals were serially imaged for 8 days, with a considerable decrease in signal at 3 days after injection. Error bars 5 SD; n 5 4 mice/group. E, Vascular permeability in a dose-dependent manner was increased by intradermal injection of histamine (0, 10 nM, or 500 mM, each in a volume of 50 mL) in phosphate-buffered saline (PBS). The left caudal thorax received no injection. IR-820 was injected intravenously and imaging was performed in triplicate on a single mouse 30 minutes after histamine injection. The image is adjusted at a minimum-maximum scale of 4 3 10 9 to 4 3 10 10 photons/s/cm 2 /steradian. F, Quantitative fluorescence signal of E shows an increase in signal from the histamine injected sites owing to vasodilation of the tissues. Error bars 5 SD.
In Vivo Near-Infrared Detection of Capillary Leak treatments or with baseline using the Hochberg step-up Bonferroni method to adjust the p values produced by repeated measures mixed model contrasts.
In Vivo Tumor Imaging
A mixed-strain wild-type mouse with a spontaneous neck tumor was injected with IR-820 by tail vein injection and imaged after 15 minutes. The animal was euthanized, and tumor tissue was collected for histology.
Lymph Node Mapping
To map ipsilateral lymph nodes, a rhabdomyosarcomaprone transgenic Myf6 ICNm/WT Pax3 P3Fm/P3Fm Trp53 F2-10/WT Rb1 Flox/Flox mouse with a foot tumor was injected with IR-820 via a direct intratumoral injection. The animal was serially imaged for 2 days. On the second day, the animal was euthanized and the tumor sample was collected for analysis, including histology.
Rose Bengal-Induced Cortical Photothrombosis Model
All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals 8 and were approved by the IACUC at UTHSCSA. Male FVB/NJ mice (Jackson Laboratory, Bar Harbor, ME) 6 to 8 weeks old were initially anesthetized at 4% isoflurane with 100% oxygen and subsequently maintained at 1.5% isoflurane through a nosecone. The depth of anesthesia was monitored by pinch withdrawal and whisker movement. Body temperature was maintained at 37uC by a feedback-controlled heating pad. The mouse hair was trimmed, and a small incision was made in the scalp to expose the skull. A custom-made stainless steel plate was glued to the bone with VetBond Tissue Adhesive (3M, St. Paul, MN). To facilitate photoactivation, a thin cranial window (<2 mm in diameter) was created over the right primary somatosensory cortex (<1.5 mm posterior to bregma and 2 mm lateral from midline) using a variablespeed electric drill (Fine Science Tools, Foster City, CA). Normal Ringer solution was periodically added to the skull to avoid damage to the underlying cortex or pial vessels by friction-induced heat. Mice were given a 0.1 mL tail vein injection of 20 mg/mL of photosensitizer rose bengal (Sigma-Aldrich) in PBS with 25 mg/mL IR-820 (Sigma-Aldrich). Photothrombotic clotting was induced by exposing the cortex under the thinned cranial window to a 543 nm laser for 15 minutes using a 0.8 NA 403 water immersion objective (Nikon, Melville, NY) to activate rose bengal over a 1 mm 2 circular area. After clotting, the plate was detached from the skull, the scalp was sutured, and the mice were carefully monitored until they recovered from anesthesia. The mice were returned to cages for subsequent noninvasive NIR fluorescent imaging.
Results
IR-820 Is a Blood Pool Contrast Agent
IR-820 is an optoelectronic agent used in laser dye applications (see Figure 1A , inset). Peak excitation and emission wavelengths were measured to be 710 and 820 nm, respectively (see Figure 1A ). In preliminary experiments, we observed that IR-820 fluorescence increased significantly when in contact with biologic tissue or serum. To determine whether the increased signal emission was a result of a simple interaction or a biochemical conversion, we measured emissions in the presence of mouse or bovine serum types treated with or without heat inactivation. The serum-bound samples showed consistently higher fluorescence intensity than the signal from unbound IR-820 (data not shown). Heat inactivation did not lead to a decreased signal, suggesting that binding was not a complex quaternary complex. To determine which proteins bind IR-820, serum-bound IR-820 samples were electrophoresed on an SDS polyacrylamide gel and imaged for NIR fluorescence (see Figure 1B ). A single 65 kDa band was detected; similar results were obtained when IR-820 was incubated with purified bovine serum albumin (see Figure 1B ).
Pharmacokinetics of IR-820 Clearance
The pharmacokinetics of IR-820 by intravenous or intraperitoneal injection was studied in vivo using two groups of Hairless SKH1/SKH1 mice (see Figure 1C ). This strain harbors a polymerase chain reaction-detectable retroviral interruption of the gene Hairless (Hr), rendering the animal fur free by 30 days of life. 9 Depending on the route of administration, the fluorescence signal intensity steadily increased and peaked 48 hours after intravenous injection or 6 hours after intraperitoneal injections (see Figure 1D ). Fecal and urinary excretions were collected daily and imaged, showing that the elimination of IR-820 was hepatobiliary (data not shown). Animals were monitored for 6 weeks after IR-820 administration without any overt signs of toxicity.
IR-820 Is Sequestered in Areas of Increased Vascular Permeability
To determine whether IR-820 would accumulate in tissue with increased vascular permeability, we used intradermal histamine diphosphate salt, an agent known to increase vascular permeability, 10 to evaluate IR-820 sequestration in a C57BL/6 mouse. The animal's skin was partially shaved and injected at different sites with 10 nM and 500 mM histamine, PBS, and no injection ( Figure 1E ). Dose-dependent increased fluorescence (p , .017) was observed at the 10 nM and 500 mM injection sites (see Figure 1F ), confirming that IR-820 was sequestered in tissue manifesting capillary leak.
IR-820 Can Be Used to Monitor the Time Course of Capillary Leak and Recovery Following Muscle Injury
A well-characterized CTX model 11 was used to determine the efficacy of IR-820 in monitoring muscle injury. CTX or NS as a control was injected intramuscularly into the anterior compartment of the right hindlimb muscles of Hairless SKH1/SKH1 mice. Normal muscle tissue morphology predominated in NS-injected specimen (Figure 2A ). However, within 1 hour after CTX injection, significant microscopic alterations were observed. Myofibers were disrupted, appearing intensely eosinophilic and separated by a protein-rich, acellular material (see Figure 2B ). Three days following CTX-induced injury, a widespread mononuclear cell inflammatory infiltrate prevailed within and around necrotic myofibers (see Figure 2C ). Inflamed and necrotic tissue was largely replaced within 7 days by small, regenerated myofibers with centrally located nuclei. Interspersed adipocytes were also present (see Figure 2D ).
Imaging was performed on three groups of Hairless SKH1/SKH1 mice receiving intramuscular injections of CTX (see Figure 2E) , NS, or no injection (noninjured group) into the right hindlimb anterior compartment 30 minutes after IR-820 injection; the left hindlimb served as a noninjected control for each animal in all three groups. To determine if CTX or NS injection in the right hindlimb altered the kinetics of IR-820 distribution or induced a systemic vascular leak, the signal intensities of the noninjected (left) hindlimbs were measured and compared in the three groups ( Figure 3A) . The noninjured group demonstrated a minimally decreased signal intensity compared with both the CTX and NS groups (p 5 .03 and , .001, respectively) at the 6.5-hour time point and an increased signal intensity compared with the NS group The first image is prior to intraperitoneal injection of IR-820; the time thereafter is in reference to IR-820 injection; cardiotoxin was injected 0.5 hours after IR-820 injection. The boxed images correspond to the histology pictures in A to D from left to right.
In Vivo Near-Infrared Detection of Capillary Leak (p # .001) at the 72-hour time point. Despite these minor differences, the signal intensities were remarkably similar, with the peak of the IR-820 signal occurring at 6 to 24 hours, suggesting that IR-820-bound albumin remained in the intravascular space in the noninjected left hindlimbs in all three groups. The time course of IR-820 signal was similar in the noninjected left hindlimbs (see Figure 3A ) to previous pharmacokinetics experiments measuring total body signal intensity after intraperitoneal injection of IR-820 (see Figure 1D ).
To determine the extent of injury-induced IR-820 leak into the extravascular space, the signal intensity of the right and left hindlimb regions was measured and the paired difference of the injected (right) hindlimb signal intensity to Figure 3 . Kinetics of IR-820 in normal and injured lower limb muscle tissue of Hairless SKH1/SKH1 mice. A, The signal intensity plot of noninjected, left hindlimbs. Inset graph demonstrates an expanded view of the early time points immediately following IR-820 injection. *p # .03 in pairwise comparison between normal saline or cardiotoxin groups compared with the noninjured group. Error bars 5 SD; n 5 3-4 mice/group. B, Paired difference of injected hindlimb and noninjected hindlimb; the time on the x-axis was measured after IR-820 injection (arrow); cardiotoxin or normal saline injection into the right hindlimb is denoted by the arrowhead. The inset graph demonstrates an expanded view of the early time points immediately following IR-820 and cardiotoxin or normal saline injection. *p # .01 in pairwise comparison between groups. #p # .03 for each time point within each group compared with baseline, defined as 0.5 hours after IR-820 injection and prior to cardiotoxin or normal saline injection. Error bars 5 SD; n 5 3-4 mice/ group. C, Ongoing vascular leak demonstrated by the paired difference of cardiotoxin (right) and normal saline (left) injected hindlimbs (arrowhead) followed by intraperitoneal IR-820 injection (arrow) 24 hours later. Time on the x-axis was measured after cardiotoxin and normal saline injections. Error bars 5 SD; n 5 2 mice/ group. the noninjected (left) hindlimb signal intensity was calculated (see Figure 3B ). As expected for the noninjured group (IR-820 intraperitoneally only), the paired difference remained near 0 throughout the study, reflecting a similar IR-820 signal in both hindlimbs and no significant variation in the paired difference time point values compared with baseline, defined as the paired difference 0.5 hours after IR-820 injection. In contrast, NS injection resulted in a paired difference peak at the 1.5-and 2.5-hour time points (p 5 .004 and .01, respectively, compared with the noninjured group) that quickly decreased to baseline and remained similar to the paired differences derived from the noninjured mice thereafter; significant elevations compared with baseline occurred at the 1.5-to 6.5-hour time points (p # .002). With CTX injection, an immediate increase in the paired difference occurred at the 1.5-hour time point, representing an increased extravascular IR-820 signal in the injected hindlimb that far exceeded the intravascular IR-820 signal of the contralateral, noninjected hindlimb and was significantly elevated compared with the NS (p , .001) and noninjured (p , .001) groups. The paired difference represented a twofold increase in the signal intensity of the CTX injected hindlimb over the noninjected hindlimb. The paired difference remained significantly elevated through the 48hour time points compared with both the NS (p , .001) and noninjured (p , .001) groups. The paired difference in the CTX group was significantly elevated compared with baseline from the 1.5-through the 72-hour time points (p # .03). These data suggest that capillary leak begins within 1.5 hours after injury and that ongoing leak or decreased clearance continues for as long as 72 hours.
To determine if an ongoing vascular leak was occurring days after CTX injury, a separate group of Hairless SHK1/SHK1 mice received IR-820 intraperitoneally 24 hours after CTX injection into the right hindlimb, concurrent with NS injection into the left hindlimb. NS injection into the contralateral hindlimb was performed to determine the vascular leak that was attributable to the CTX rather than injury induced by the needle or fluid volume. In this experiment, the signal intensity of the NS hindlimbs (data not shown) was similar to the noninjected IR-820 kinetics (see Figure 3A ). Next, the paired difference between the CTX-injected right hindlimb and the NS control left hindlimb was calculated (see Figure 3C ). The extravascular IR-820 signal peaked 48 hours after CTX injection (24 hours after IR-820 injection) and was similar to baseline by the 144-hour time point. In contrast to the twofold increase in signal intensity when IR-820 injection preceded CTX injection (see Figure 3B ), the signal intensity of the CTX limb was increased 40% over the NS limb when IR-820 was injected 24 hours after CTX injection. In combination, these data suggest that, initially, a large vascular leak occurs within hours of injury, and a smaller but ongoing vascular leak occurs for at least 48 hours after injury.
IR-820 Is a Contrast Agent for a Multitude of Diseased Tissues
To determine whether IR-820 could be used as a contrast agent for tumors, a mixed-strain mouse bearing a neck tumor was injected with IR-820 via the tail vein and imaged 15 minutes later. NIR fluorescence was seen in a distribution characteristic of a blood pool contrast agent (bare skin of paws, tail, and highly vascular region of the nose) ( Figure 4A ), yet a very significant amount of signal emanated from the tumor mass (28.4% of total flux). Tumor histology consistent with lymphoma is shown in the inset. Small metastases, however, were difficult to visualize in similar experiments (data not shown).
To demonstrate the use of IR-820 for lymph node mapping, we injected IR-820 directly into a rhabdomyosarcoma tumor on the left foot of a transgenic Myf6 ICNm/WT Pax3 P3Fm/ P3Fm Trp53 F2-10/WT Rb1 Flox/Flox mouse. Signal was present in the primary tumor, as well as the ipsilateral popliteal lymph node and the proximal superficial inguinal lymph node (see Figure 4B ), as confirmed by necropsy. Histologically, the primary tumor was consistent with rhabdomyosarcoma (see Figure 4B , inset), but only the popliteal lymph node (which bore the highest fluorescence) contained metastatic tumor cells.
Thrombotic stroke is a nononcologic example of disordered vascular integrity. Thromboses reroute cerebral circulation, causing regions of focal ischemia and potential damage to the blood-brain barrier (BBB) at the site of each thrombus. To assess whether BBB permeability could be imaged in vivo, noninvasive, photothrombotic vascular occlusions were induced by irradiating a 1 mm 2 circular region of the mouse cortex following tail injection of the photosensiting dye rose bengal. When rose bengal dye is excited with green light (543 nm), the dye fluoresces red and the brain blood vessels are easily observed using optical microscopy. However, when rose bengal is excited for prolonged periods, singlet oxygen molecules are generated, locally damaging the blood vessel walls and inducing thrombosis. BBB permeability was tested by tail vein injection of IR-820 at various periods subsequent to the initial photothrombosis. IR-820 leakage from the intravascular compartment was interpreted to reflect increased BBB permeability induced by the photothrom-botic stroke. As expected for damaged blood vessels, significant IR-820 fluorescence was observed in regions of the cortex that were in close proximity to the photothrombosed area (see Figure 4C ). Extravasation of the dye occurred over an area much larger than the initial lesion (see Figure 4C , inset). However, IR-820 fluorescence was not observed in control mice that underwent identical procedures without tail vein injections of rose bengal (data not shown).
Discussion
IR-820 is a novel and inexpensive NIR blood pool contrast agent (l excitation 710 nm, l emission 820 nm) with enhanced biologic fluorescence attributable to albumin binding in the serum. Clearance is hepatobiliary and is nearly complete (99%) 8 days after intraperitoneal or intravenous injection. IR-820 clearance is similar to the clearance of albumin (halflife 5 35 hours; 5 half-lives 5 7.3 days). 12 We speculate that the slight difference in intravenous versus intraperitoneal kinetics may be attributable to increased portal/hepatobiliary clearance with intraperitoneal injection. By either route of delivery, near-complete clearance (99%) occurred after 8 days of IR-820 administration.
Furthermore, we have shown that IR-820 accumulates in injured muscle, and we also demonstrate that IR-820 is sequestered in several disease conditions with increased vascular permeability, including tumors and stroke.
Optical contrast agents are ideally suited to wholeanimal studies. In the NIR electromagnetic spectrum, tissue absorption and scattering are at a minimum, thereby providing a high level of signal penetration. This region of spectra is well established to have the minimum penetration owing to the optical properties of the oxy-and deoxyhemoglobin. 13 Disadvantages of optical imaging in general include dampening of the signal through skin that is pigmented or contains hair. However, hair removal by clipping or depilatory agents can facilitate the use of IR-820 in a diverse array of animal species. To demonstrate the use of IR-820 to monitor tissue injury and recovery over time, we used a well-characterized CTX injury model. 11 CTX contains lytic factors whose primary mechanism of action is forming pores that depolarize and degrade the muscle plasma membrane. 14 CTX injection results in muscle necrosis followed by an inflammatory and regenerative response similar to the injury repair response observed in muscle following an ischemic injury. 11, 15 IR-820 injected into the intraperitoneal space is absorbed into the vascular system, binds to serum albumin, and emits a reproducible intravascular signal as demonstrated by the noninjured group and the noninjected hindlimbs of the CTX and NS groups. Our findings demonstrate an increased IR-820 signal in muscle after both mild (NS injection) and severe (CTX injection) injury and that the severity of injury influences the Figure 4 . In vivo imaging of diseased animals using IR-820. A, A mouse bearing a neck tumor was imaged 15 minutes after injection of 100 mL of IR-820 intravenously through tail vein injection. A large portion (28.4% of total) of the IR-820 fluorescence was concentrated in the viable solid tumor region. The inset shows the histology, which was consistent with lymphoma. The image has been displayed at a minimum-maximum scale of 3 3 10 8 to 2 3 10 9 photons/s/cm 2 /steradian. B, One hundred microliters of IR-820 was administered directly into the foot tumor (tu) of a transgenic Myf6 ICNm/WT Pax3 P3Fm/ P3Fm Trp53 F2-10/WT Rb1 Flox/Flox mouse and imaged 24 hours after injection. Fluorescence signal is present at the tumor site and the popliteal (arrow) and inguinal (arrowhead) lymph nodes. Histology demonstrates rhabdomyosarcoma tumor cells adjacent to normal skeletal muscle (skm) (inset). The image is thresholded at a minimum-maximum scale of 5 3 10 8 to 1 3 10 9 photons/s/cm 2 /steradian. C, IR-820 contrast agent was given via tail vein injection into a mouse after induction of a thrombotic stroke. The blue region shows the site of the stroke, and the red region shows the swelling in the area of tissue injury caused by the stroke. The inset shows the gross picture of the mouse with a stoke. A minimum-maximum scale of 8 3 10 8 to 6 3 10 9 photons/s/cm 2 /steradian has been used to display the IR-820 image.
intensity of the IR-820 signal. CTX causes muscle necrosis with disruption of the capillary network. 14 The intravascular, albumin-bound IR-820 leaked into the CTX-injured muscle immediately postinjection presumably owing to increased permeability from disruption of the endothelial barrier function. Normally, the endothelial barrier function is maintained by a continuous membrane composed of semipermeable endothelial cells. 16 Disruption of the endothelial barrier function results in extravasation of fluid and proteins, including albumin, leading to tissue edema 17 and, in the present study, an extravascular IR-820 signal. In addition, endothelial dysfunction from neighboring regions of intact muscle may have also contributed to extravasation of IR-820-bound albumin. Consistent with the histology demonstrating diffuse myonecrosis, the IR-820 signal difference peaked at 1 hour after CTX injection and remained elevated for several days. The paired difference in the CTX-injured group remained significantly increased until the 72-hour time point, which histologically corresponded to macrophage infiltration into the injured muscle. 11 Macrophages phagocytize necrotic myofibers 18 and may also assist in the clearance of extravascular albumin, thus decreasing the IR-820 signal. Resolution of the extravascular IR-820 signal may result from a combination of vascular leak cessation and effective IR-820-bound albumin removal from the extravascular space. A continued, multiday IR-820 leak was demonstrated by injecting IR-820 24 hours subsequent to CTX injection. Thus, the extravascular IR-820 signal is likely determined by the kinetics of the vascular leak versus IR-820-bound albumin removal. Interestingly, CTX injury did not induce any systemic increase in vascular permeability as the absolute signal intensity of the control limbs was remarkably similar in noninjured and NS-and CTXinjected mice. Thus, the CTX model provides an example of how the timing of IR-820 can reveal complementary information on the time course of capillary leak and the clearance of interstitial fluid.
In summary, IR-820 is an effective, low-cost alternative to other commercial blood pool contrast agents. 19 This NIR contrast agent is ideally suited to preclinical applications requiring qualitative and quantitative assessment of injured tissue and diseased tissue with capillary leak, including tumors and stroke.
